Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the
"Company" or
"Blueberries"), a Latin American licensed
producer of medicinal cannabis and cannabis-derived products, is
pleased to announce that the Board of Directors has appointed Mr.
Camilo Villalba as Chief Executive Officer of the Company. Mr.
Villalba, who is a co-founder of Blueberries and currently serves
as Chief Operating Officer, will lead the Company's next phase of
operational development, with initial exports expected during the
first half of 2020. Dr. Patricio Stocker will continue to support
Blueberries as a Senior Strategic Consultant focused on expanding
the Company's international cannabis sales and other strategic
initiatives.
"The Board of Directors and I are pleased that
Mr. Villalba has agreed to utilize his business leadership skills,
operational expertise, and industry knowledge to guide the
Company's future growth," said Christian Toro, Executive Chairman
of Blueberries. "Working alongside our experienced management team
including Eduardo Molinari as Chief Marketing Officer and Ian
Atacan as Chief Financial Officer, we are confident that with Mr.
Villalba at the helm, our company is prepared for future success.
We thank Dr. Stocker for his contribution to the company and
guidance through the preoperational and development phase and look
forward to his contributions in expanding the company’s
international footprint."
"Blueberries has made tremendous progress in a
relatively short period of time and are now among the leading group
of operators in Colombia," stated Mr. Villalba. "Now that the
infrastructure is in place and commercial cultivation has begun
with our approved strains, we are well positioned to ramp up
production and meet local and international demand through our
company’s owned facilities and agreements with contract growers. I
am looking forward to guiding Blueberries in this process as well
as establishing a solid operation capable of adapting to the global
market conditions."
Mr. Villalba is a co-founder of Blueberries and
has been leading the corporate and operational areas since before
the Company became the first Colombian cannabis producer listed on
the Canadian Securities Exchange. An entrepreneur and business
strategist, Mr. Villalba began his career in the Energy sector,
providing consulting services to diverse companies in Latin
America. Before founding Blueberries, Mr. Villalba was a
private equity investor and supported the creation and growth of
ventures in different Latin American markets, including Colombia
and Mexico. Mr. Villalba has lived and worked in several cities
around the globe, developing a robust international business
network.
"When I took on the role of CEO of Blueberries,
my main objective was to drive the Company to start operations in
our facilities by achieving all necessary milestones on the
regulatory, agricultural and extraction facets of the business,"
said Dr. Stocker. "Having achieved this goal, it is time for me to
focus on helping the company enter new markets and hand over
leadership of operations to Mr. Villalba, whose leadership I am
certain will help Blueberries succeed in the next phase of its
development."
"Dr. Stocker has been critical in establishing
the operations at Blueberries and preparing the company for
commercial extraction and sales by building an incredibly capable
professional management team and guiding the company during this
important juncture," said Mr. Villalba. "I am excited about leading
the company on its path to becoming a prominent supplier of
naturally grown premium quality cannabis."
About Blueberries Medical
Corp.Blueberries is a Latin American licensed producer of
naturally grown premium quality cannabis with its primary
operations ideally located in the Bogotá Savannah of central
Colombia and operations being initiated in Argentina. The Company
is led by a specialized team with proprietary expertise in
agriculture, genetics, extraction, medicine, pharmacology, and
marketing. Blueberries is fully licensed for the cultivation,
production, domestic distribution, and international export of CBD
and THC-based medical cannabis in Colombia. Blueberries is
positioned to become a leading international supplier of naturally
grown, processed, and standardized medicinal-grade cannabis oil
extracts and related products with its leading scientific
expertise, agricultural advantages, and distribution
arrangements.
Additional information about the Company is
available at www.blueberriesmed.com. For more information, please
contact:
Camilo Villalba, Chief Executive Officer
cvillalba@blueberriesmed.com Tel: +57 (313) 483 0131
Ian Atacan, Chief Financial
Officeriatacan@blueberriesmed.com Tel: +1 (416) 562 3220
Jessika Angarita, Pacta Relations
angarita@pactarelations.com Tel: +1 (305) 877 4710
Cautionary Note Regarding
Forward-Looking InformationThis news release contains
"forward-looking information" and "forward-looking statements"
(collectively, "forward looking statements") within the meaning of
the applicable Canadian securities legislation. All statements,
other than statements historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that involves
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or
performance (often but not always using phrases such as “expects”,
or “does not expect”, “is expected”, “anticipates” or “does not
anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. In this news release, forward looking
statements relate, among other things, to: closing of the proposed
transactions and achieving milestones in 2019 as contemplated, or
at all, ability to expand distribution networks, ability to expand
and upgrade the Company’s cultivation facilities in Colombia,
internal expectations, expectations regarding the ability of the
Company to access new Latin American and international markets, the
ability to attract and retain new customers, and future expansion
plans including development of the cultivation, production,
industrialization and marketing of cannabis for commercial and
scientific purposes.
These forward-looking statements are based on
reasonable assumptions and estimates of management of the Company
at the time such statements were made. Actual future results may
differ materially as forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to
materially differ from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Such factors, among other things, include: fluctuations
in general macroeconomic conditions; fluctuations in securities
markets; expectations regarding the size of the Colombian and
international medical cannabis market and changing consumer habits;
the ability of the Company to successfully achieve its business
objectives; plans for expansion; political and social
uncertainties; inability to obtain adequate insurance to cover
risks and hazards; and the presence of laws and regulations that
may impose restrictions on cultivation, production, distribution
and sale of cannabis and cannabis related products in Colombia,
Argentina and elsewhere; and employee relations. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes, or believed at the
time, to be reasonable assumptions, the Company cannot assure
shareholders that actual results will be consistent with such
forward-looking statements, as there may be other factors that
cause results not to be as anticipated, estimated or intended.
Readers should not place undue reliance on the forward-looking
statements and information contained in this news release. The
Company assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change, except as required by law.
Additional information regarding the Company,
and other risks and uncertainties relating to the Company's
business are contained under the heading "Risk Factors" in the
Company's Listing Statement dated January 31, 2019 filed on its
issuer profile on SEDAR at www.sedar.com.
No stock exchange, securities commission or
other regulatory authority has approved or disapproved the
information contained herein.
Blueberries Medical (CSE:BBM)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Blueberries Medical (CSE:BBM)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025